IMU (ASX) no recruitments? no patients dosed?

Originally posted by davybabyk ↑

Patience is required when recruiting patients, lol.
The only site actively recruiting so far is:

Column 1 Column 2

1 Division of Oncology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University Recruiting

2 Chiang Mai, Thailand

The "Inclusion" and "Exclusion" criteria are very detailed. It does take time to find candidates:

Criteria
Inclusion Criteria:

Patient has been informed of the investigational nature of this study and has given written informed consent in accordance with institutional, local, and national guidelines;

Age ≥ 20 years old;

Life expectancy of at least 12 weeks;

No prior chemotherapy or radiotherapy for advanced gastric or GEJ cancer within 6 months prior to Day 0;

Metastatic gastric or GEJ adenocarcinoma, or locally advanced disease not amenable to surgical resection;

HER2/neu overexpression (3+ by immunohistochemistry (IHC) or if IHC 2+ confirmed by fluorescent in situ hybridization [FISH] or chromogenic in situ hybridization [CISH]);

ECOG performance status 0-1;

At least one measurable lesion as defined by RECIST 1.1 criteria;

Adequate left ventricular ejection function at baseline, defined as LVEF > 50% by echocardiogram or MUGA scan (Multi Gated Acquisition Scan);

Adequate hematologic function: absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet count ≥ 100 x 109/L, and hemoglobin ≥ 9 g/dL;

Adequate liver function evidenced by bilirubin ≤ 1.5 x laboratory upper limit of normal [ULN], and ALT and AST ≤ 3 x laboratory ULN if no liver involvement or ALT and AST ≤ 5 times laboratory ULN with liver involvement;

Adequate renal function (creatinine ≤ 1.5 x laboratory ULN);

Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Male and female patients of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 28 days after the last dose of assigned treatment (see section 4.3 for details). A patient is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.

Exclusion Criteria:

Previous treatment with trastuzumab or any other HER2/neu targeting antibody or agent;

Continuous systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 4 weeks prior to first dose of study treatment. Inhaled or topical steroids and physiological replacement doses of up to 10 mg daily prednisone equivalents are permitted in the absence of active auto-immune disease;

Prior organ transplant;

Patient not considered a candidate for 5-FU, capecitabine, or cisplatin chemotherapy;

History of documented congestive heart failure; angina pectoris requiring antianginal medication; evidence of transmural infarction on ECG; poorly controlled hypertension; clinically significant valvular heart disease; high risk uncontrolled arrhythmias; or New York Heart Association (NYHA) class II heart disease;

If on warfarin (Coumadin®) or other vitamin K antagonists;

Concurrent active malignancy except for adequately controlled limited basal cell carcinoma of the skin;

Peripheral neuropathy or hearing loss of NCI CTCAE Grade > 2;

History of uncontrolled seizures, central nervous disorders or psychiatric disability judged by the investigator to be clinically significant and precluding informed consent, participation in the study, or adversely affecting compliance to study drugs;

Active infection requiring IV antibiotics;

Positive for human immunodeficiency virus (HIV) (HIV 1/2 antibodies) or active hepatitis B (HBsAg reactive) or active hepatitis C (HCV ribonucleic acid [RNA] qualitative) infection;

Pregnant or lactating females;

Major surgery within 4 weeks prior to study entry. Minor surgery (excluding diagnostic biopsy) within 1 week prior to study entry;

Has received a live-virus vaccination within 4 weeks of first study vaccination. Seasonal flu vaccines that do not contain live virus are permitted;

Current or recent (within 4 weeks of first IMU-131 vaccination) treatment with another investigational drug or participation in another investigational study.

This is one of the reasons Clinical Trials take time. Get the recruitment wrong and you invalidate the results.

I'm quite happy for this to take as long as it needs to take. It needs to be done very carefully and correctly.

Cheers

Dave

Expand

Agree Dave. I've been notified that broker meetings are being arranged for the first week of Feb by Leslie today. Would guess good news is pretty close.

No.	Vol.	Price($)
1	25110	4.5¢

No.

Vol.

Price($)

25110

4.5¢

Price($)	Vol.	No.
4.6¢	2719659	16

Price($)

Vol.

No.

4.6¢

2719659

No.	Vol.	Price($)
31	3653887	0.044
33	4039033	0.043
30	2277376	0.042
21	2577275	0.041
55	5674476	0.040

No.

Vol.

Price($)

3653887

0.044

4039033

0.043

2277376

0.042

2577275

0.041

5674476

0.040

Price($)	Vol.	No.
0.045	699387	6
0.046	1761664	13
0.047	3580569	13
0.048	1650196	11
0.049	2151303	11

Price($)

Vol.

No.

0.045

699387

0.046

1761664

0.047

3580569

0.048

1650196

0.049

2151303

(20min delay)
Last 4.5¢		Change 0.000(0.00%)		Mkt cap ! $334.7M

Open	High	Low	Value	Volume
4.6¢	4.6¢	4.5¢	$151.4K	3.343M

no recruitments? no patients dosed?, page-5

HotCopper users bullish on Spartan Resources' latest gold find right near Pepper deposit

Helix extends its copper footprint at Bijoux in NSW with latest drill results

ACCC greenlights Sigma Healthcare, Chemist Warehouse merger

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

	Column 1	Column 2
1	Division of Oncology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University	Recruiting
2	Chiang Mai, Thailand

no recruitments? no patients dosed?, page-5

Top Stories

HotCopper users bullish on Spartan Resources' latest gold find right near Pepper deposit

Helix extends its copper footprint at Bijoux in NSW with latest drill results

ACCC greenlights Sigma Healthcare, Chemist Warehouse merger

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News